Hyoscyamus niger

# Research Output: Hyoscyamus niger

---

## Botanical Identity

**Accepted binomial:** *Hyoscyamus niger* L.  
**Family:** Solanaceae (order Solanales)  
**Tribe:** Hyoscyameae  
**First published:** *Species Plantarum*: 179 (1753) by Carl Linnaeus [Ref 15]  
**Common names:** Black henbane, stinking nightshade, hog's bean

**Synonyms (selected):** *Hyoscyamus pallidus* Waldst. & Kit. ex Willd., *Hyoscyamus bohemicus* F.W.Schmidt, *Hyoscyamus agrestis* Kit., *Hyoscyamus lethalis* Salisb., *Hyoscarpus niger* (L.) Dulac — 30 documented synonyms total per POWO [Ref 15].

**Growth habit:** Annual or biennial herb; grows primarily in the temperate biome [Ref 15].

**Native range:** Mediterranean to Iran — including Albania, Algeria, Bulgaria, Greece, Iran, Iraq, Italy, Lebanon-Syria, Morocco, Portugal, Spain, Turkey, and Tunisia [Ref 15].

**Introduced range:** Now established across temperate regions worldwide, including North America (Canada, USA), Asia (China, Japan, Korea), and Oceania (Australia, New Zealand) [Ref 15]. Introduced to the Americas as a medicinal herb.

**Cultivation status:** Wild-harvested primarily; cultivated for pharmaceutical alkaloid production in some regions. Listed as a noxious weed in multiple US states (Washington, California, Colorado, Idaho, New Mexico, Nevada, South Dakota, Wyoming) and in Alberta, Canada [Ref 28]. A single plant can produce up to approximately 500,000 seeds, contributing to its invasive spread.

**Morphological notes and misidentification risks:**  
The plant has sticky, hairy leaves and pale yellow flowers with purple veining. The fetid odor is a distinguishing feature. Per Fatur & Kreft (2020 [Ref 2]), *H. niger* is primarily ingested accidentally when mistaken for other plants — distinguishing it from *Datura stramonium* (teen drug use) and *Atropa belladonna* (berry misidentification). Misidentification with edible umbellifers, beets, and other garden herbs has been documented. Confusion with other Solanaceae family members is common among contemporary users (Fatur & Kreft 2021 [Ref 29]).

**Discrepancy with brief seed data:** The brief listed "no seed data" for all botanical identity fields. The above data fills those gaps from primary sources.

---

## Alkaloid / Cannabinoid Profile

### Primary Alkaloids

**Hyoscyamine (L-hyoscyamine)**  
- PubChem CID: 154417 | Molecular formula: C₁₇H₂₃NO₃ | MW: 289.4 g/mol | InChIKey: RKUNBYITZUJHSG-VFSICIBPSA-N  
- The pharmacologically active L-enantiomer of atropine (the racemic mixture has CID 174174, same formula/MW)  
- Tropane alkaloid; primary muscarinic receptor antagonist; predominant in most *Hyoscyamus* species at low doses predominantly mediates peripheral anticholinergic effects

**Scopolamine (L-hyoscine)**  
- PubChem CID: 3000322 | Molecular formula: C₁₇H₂₁NO₄ | MW: 303.35 g/mol | InChIKey: STECJAGHUSJQJN-USLFZFAMSA-N  
- The 6,7-epoxide derivative of hyoscyamine; superior CNS penetration; produces sedation, amnesia, and at higher doses delirium and hallucinations  
- Characteristic of *H. niger*: this species has a relatively high scopolamine-to-hyoscyamine ratio compared to other *Hyoscyamus* species (Shim et al. 2022 [Ref 1])

### Quantified Concentrations

**HPLC-DAD data from H. niger roots** (Ahmadpour et al. 2024 [Ref 4]):  
- Hyoscyamine: 164.72 µg/g dry weight (optimal ultrasound extraction)  
- Scopolamine: 209.23 µg/g dry weight  
- Scopolamine exceeds hyoscyamine in roots, consistent with *H. niger*'s biochemical profile

**Total alkaloid percentages by plant part** (European strains, from Alizadeh et al. 2014 [Ref 3]):  
- Leaves: ~0.17% total alkaloids  
- Roots: ~0.08% total alkaloids  
- Seeds: ~0.05% total alkaloids  
- *Note:* Despite lower percentage, seeds are described as having the "highest concentration of alkaloids" in some sources, reflecting that seeds are consumed in larger amounts relative to body weight

**Geographic chemotype variation:**  
Egyptian strains contain significantly higher total alkaloids (0.7–1.5%) compared to European strains (Alizadeh et al. 2014 [Ref 3]). This represents a >10-fold difference and has direct safety implications for dose estimation.

**Hairy root culture baseline** (wild-type, Guo et al. 2018 [Ref 19]):  
- Hyoscyamine: ~54 µg/g DW (wild-type hairy roots)  
- Scopolamine increased ~4.70-fold in transgenic lines vs wild type, establishing baseline for comparison

**Minor alkaloids:**  
- **Anisodamine** — confirmed in *H. niger* by HPLC (Jaremicz et al. 2014 [Ref 6]; Li et al. 2017 [Ref 20])  
- **Cuscohygrine** — primarily in roots; 26.5 mg/g DW in hairy root bioreactor cultures (Jaremicz 2014 [Ref 6])  
- **Apoatropine** — present in whole plant (Alizadeh 2014 [Ref 3])  
- These are supporting constituents; their pharmacological contribution in whole-plant preparations is poorly characterized in published literature

### Biosynthetic Pathway

Tropane alkaloid biosynthesis in *H. niger* follows: ornithine/arginine → putrescine → N-methylputrescine → tropinone → tropin/pseudotropin → hyoscyamine → 6β-hydroxyhyoscyamine → scopolamine. The key terminal step is catalyzed by hyoscyamine 6β-hydroxylase (H6H), a 2-oxoglutarate-dependent dioxygenase first purified and characterized from *H. niger* root cultures (Hashimoto & Yamada 1987 [Ref 7]). H6H catalyzes both the hydroxylation of hyoscyamine and the subsequent epoxidation to scopolamine. The aromatic amino acid aminotransferase HnArAT3 gene in *H. niger* provides phenyllactic acid for the esterification step (Li et al. 2017 [Ref 20]).

Alkaloid synthesis occurs primarily in roots; storage and accumulation occur in leaves (Hashimoto & Yamada 1987 [Ref 7]; Kohnen et al. 2018 [Ref for Duboisia context]).

### How Preparation Alters Alkaloid Ratios

- **Aqueous extraction (tea):** Water preferentially extracts both alkaloids; scopolamine and hyoscyamine are both water-soluble; relative ratios maintained but yield depends heavily on pH and temperature  
- **Methanol extraction:** 100% methanol at 45°C with ultrasound optimizes hyoscyamine yield (164.72 µg/g DW); ~98.5% methanol at 25°C optimizes scopolamine (209.23 µg/g DW) — different extraction conditions differentially favor each alkaloid (Ahmadpour 2024 [Ref 4])  
- **Smoking/burning:** Pyrolysis partially degrades alkaloids; however scopolamine and hyoscyamine survive partial combustion — no published quantitative data on alkaloid yield from smoking *H. niger* specifically  
- **No published data** on decarboxylation-equivalent step affecting tropane alkaloids (unlike cannabis); these alkaloids do not require thermal activation

---

## History & Ethnobotany

### First Scientific Description

*Hyoscyamus niger* was formally described by Carl Linnaeus in *Species Plantarum*: 179 (1753), the founding work of modern botanical nomenclature [Ref 15]. However, the plant was known to European botanists and physicians many centuries earlier under various names.

### Ancient and Classical Use

Use of *H. niger* dates to at least 4,000 BC throughout southern and central Europe and Eurasia [Ref 27]. The plant was recorded in ancient Greek medicine as *Herba Apollinaris* — the "plant of Apollo" — and was used by priests and priestesses at oracular sites including Delphi to induce trance states facilitating communion with divine realms [Ref 27].

Pedanius Dioscorides (1st century AD) documented *H. niger* as a sedative and analgesic in *De Materia Medica*; he recommended it for pain relief and sleep induction. Pliny the Elder described it as "of the nature of wine and therefore offensive to the understanding" — an early acknowledgment of its intoxicating properties [Ref 27]. Celsus also documented clinical uses.

Archaeological evidence is extensive: *H. niger* seeds have been found at 65 of 83 Roman-period archaeological sites in the Netherlands. A hollowed sheep/goat bone plugged with birch-bark tar and containing over 1,000 *H. niger* seeds was recovered from a Roman site dated to approximately AD 70–100 [Ref 27], suggesting deliberate medicinal or ritual storage of seeds.

### Viking and Norse Culture

*H. niger* was one of the most important ritual plants of the Vikings and Druids. Henbane seeds have been found in a Viking grave at Fyrkat, Denmark, first described in 1977 [Ref 27]. The anticholinergic symptoms induced by *H. niger* — including agitation, aggression, confusion, and physical endurance — have been proposed as potentially consistent with the berserker rage state described in Norse sagas (traditional use account; not clinically confirmed) [Ref 27].

### Medieval Europe

In medieval Europe, *H. niger* became strongly associated with witchcraft. It was a documented ingredient in "witches' ointments" or "flying ointments" applied transdermally — the anticholinergic delirium, including sensations of flight, accounts for the folkloric association between witches and broomsticks [Ref 27].

*H. niger* was a beer additive (alongside other herbs in the mixture called *gruit*) in northern European brewing before hops were universally adopted. The Bavarian Purity Law of 1516 (*Reinheitsgebot*) specifically banned ingredients other than barley, hops, yeast, and water, effectively prohibiting henbane beer [Ref 27].

Teodorico Borgognoni (1205–1296), considered a forerunner of modern surgical anesthesia, included narcotic plants (likely including henbane) in his anesthetic preparations recorded in *Cyrurgia seu filia principis* (Cavalloro et al. 2023 [Ref 25]).

Shakespeare referenced "henbane tincture" in *Hamlet* (Act 1, Scene 5) as the murder weapon used against Hamlet's father — reflecting its established reputation as a potent poison in Elizabethan England.

### Islamic and Middle Eastern Traditional Medicine

Ibn Sina (Avicenna, 980–1037 AD) described *H. niger* in *Canon of Medicine* for pain relief, including toothache and joint pain — flag: this claim is widely cited but the original Arabic source was not directly verified in this research pass.

*H. niger* continues to be used in traditional medicine in Morocco (High Atlas Tashelhit-speaking communities) in contemporary ethnobotanical surveys (Teixidor-Toneu et al. 2016 [Ref from OpenAlex]).

### Regulatory and Pharmaceutical History

The alkaloids hyoscyamine and scopolamine became important pharmaceutical compounds in the 19th and 20th centuries:  
- Scopolamine was one of the first drugs made commercially available in a transdermal delivery system (TTS-patch) for motion sickness prevention (Renner 2005 [Ref 8])  
- Both alkaloids are listed on the WHO List of Essential Medicines  
- They have FDA-approved formulations as pharmaceuticals  
- Commercial-scale alkaloid production now primarily uses hybrid *Duboisia myoporoides* × *D. leichhardtii* crops in Australia rather than *H. niger* (Kohnen et al. 2018)

---

## Neuroscience & Mechanism

### Primary Receptor Targets

Both hyoscyamine and scopolamine are **competitive, non-selective muscarinic acetylcholine receptor (mAChR) antagonists**, blocking the neurotransmitter acetylcholine at M1, M2, and M3 muscarinic receptor subtypes in the central and peripheral nervous system (Shim et al. 2022 [Ref 1]).

Peripheral muscarinic blockade produces: pupil dilation (mydriasis), reduced salivation, reduced bronchial secretion, bronchodilation, reduced GI motility, tachycardia (M2 block), urinary retention, and inhibition of sweating.

Central muscarinic blockade produces: sedation, amnesia (scopolamine preferentially), confusion, delirium, and at high doses auditory/visual/tactile hallucinations.

**Key difference between alkaloids:**  
- **Scopolamine** has superior blood-brain barrier penetration; produces sedation, amnesia, and antiemetic effects at therapeutic doses; causes delirium and hallucinations at toxic doses  
- **Hyoscyamine/atropine** has predominantly peripheral effects at low-moderate doses; central effects emerge at higher doses or with direct CNS exposure  
- The ratio of CNS-to-peripheral effects makes scopolamine more psychoactive and more dangerous for CNS toxicity (Shim et al. 2022 [Ref 1]; Alizadeh 2014 [Ref 3])

### Pharmacokinetics by Route

**Scopolamine — Oral:**  
- Bioavailability: 3–27% (highly variable between individuals; range confirmed across studies) (Putcha et al. 1989 [Ref 10]; Renner et al. 2005 [Ref 8])  
- Tmax: approximately 0.5 h after oral administration (Renner 2005 [Ref 8])  
- Plasma half-life: 4.5 ± 1.7 h (Putcha 1989 [Ref 10])  
- Extensive first-pass metabolism suggested by low urinary excretion of unchanged drug (~2.6%)  
- Metabolic pathway: glucuronide conjugation (major); oxidative demethylation by CYP3A4 (Renner 2005 [Ref 8])

**Scopolamine — Intravenous:**  
- Clearance (CL): 205 ± 36.6 L/h  
- Volume of distribution (Vd): 363 ± 66.7 L  
- Distribution half-life (α): 2.9 ± 0.67 min  
- Terminal half-life (β): 105.4 ± 9.94 min  
- Peak serum concentration after 0.5 mg IV: ~4.66 ng/mL  
(Ebert et al. 2001 [Ref 9])

**Scopolamine — Intramuscular:**  
- Absolute bioavailability: 57% ± 8%  
- Peak serum concentration after 0.5 mg IM: ~0.96 ng/mL  
(Ebert et al. 2001 [Ref 9])

**Scopolamine — Transdermal (TTS-patch):**  
- 1.5 mg reservoir patch; priming dose 140 µg; releases 0.5 mg over 72 h (rate: 5 µg/h)  
- Steady-state Cmax: ~100 pg/mL (range 11–240 pg/mL) reached ~8 h post-application  
- Plateau maintained for 72 h: 56–245 pg/mL  
(Renner 2005 [Ref 8])

**Note:** Published pharmacokinetic data are for purified scopolamine formulations, not crude *H. niger* plant preparations. The effective bioavailability of alkaloids consumed via plant material (tea, seeds, oral preparation) will differ due to the matrix, fiber content, and variable alkaloid concentration.

### CYP Enzyme Involvement and Drug Interactions

Scopolamine undergoes oxidative demethylation via **CYP3A4** (Renner 2005 [Ref 8]):  
- **Grapefruit juice** (CYP3A4 inhibitor): co-administration with 150 mL grapefruit juice increased scopolamine AUC₀₋₂₄ to approximately 142% of control values; absolute oral bioavailability increased from 3–27% range to 6–37%; Tmax prolonged from ~30 min to ~60 min (p < 0.001) [Ref 8]. This interaction has a clear pharmacokinetic mechanistic basis.

**Pharmacodynamic interactions (additive anticholinergic burden):**  
- Tricyclic antidepressants (e.g., amitriptyline, imipramine): strong anticholinergic properties; additive risk with H. niger alkaloids for delirium, urinary retention, hyperthermia  
- Antihistamines (e.g., diphenhydramine, hydroxyzine): additive anticholinergic effects  
- Antipsychotics (phenothiazines, clozapine): additional anticholinergic burden  
- Benzodiazepines and alcohol: pharmacodynamic CNS depression additive with sedative effects of scopolamine  
- Cholinesterase inhibitors (physostigmine, donepezil): antagonize anticholinergic effects; physostigmine used therapeutically to reverse delirium  
*Evidence basis for these interactions: pharmacodynamic (mechanism well established); direct clinical case reports for specific drug + H. niger not found in published literature*

### Blood-Brain Barrier

Scopolamine readily crosses the BBB (accounts for its CNS effects). It also crosses the placenta — use in pregnancy requires clinical observation (Renner 2005 [Ref 8]).

---

## Effects & Dose by Preparation

### Important Framing Note

**No safe or intentional dose for human consumption of *H. niger* preparations has been established in published clinical or pharmacological literature.** The data below derives entirely from poisoning case reports and toxicological reviews, not controlled human trials. The alkaloid content of *H. niger* plant material varies enormously (>10-fold between geographic strains, variable between plant parts and growing conditions). These factors make dose estimation for plant preparations clinically unreliable.

### Published Dose-Effect Data (From Poisoning Cases)

**Oral (flowers, seeds, or leaves by mistake or deliberate ingestion):**  
- Approximately 4 flowers are sufficient to induce clinical manifestations in a pre-school child (Alizadeh et al. 2014 [Ref 3]) — *note: this is presented without a specific citation in the source; flagged for human review*  
- One documented case of deliberate henbane flower chewing (to produce euphoria) resulted in acute anticholinergic poisoning in an adult (Sands & Sands 1976 [Ref 22])

**Clinical effect profile from poisoning literature:**  
The dominant effects of acute *H. niger* poisoning are anticholinergic in nature — not euphoric. Clinical series report:  
- Mydriasis: 94.8% of cases  
- Restlessness: 89.5%  
- Hallucinations (auditory, visual, tactile): 89.5%  
- Tachycardia, dry mouth, warm flushed dry skin, hyperthermia  
- Urinary retention, constipation  
- Confusion, disorientation, delirium, combative behavior  
- Blurred vision, photophobia  
- Nausea, vomiting, headache  
- At severe doses: arrhythmia, convulsion, coma  
(Alizadeh et al. 2014 [Ref 3])

**Duration:**  
- Approximately 85% of alkaloids excreted within 24 hours in poisoning cases (Alizadeh 2014 [Ref 3])  
- Most clinical effects resolve within 24 h with supportive care  
- Severe cases may require 1–2 days management  
- No published data on onset time for plant preparations specifically (onset for purified scopolamine oral: ~30 min)

**Effect modifiers:**  
- Geographic strain: Egyptian *H. niger* has 0.7–1.5% alkaloids vs. European ~0.05–0.17%; the same mass of plant material from different origins can be 10× more potent  
- Plant part: leaves > roots > seeds (by total alkaloid %)  
- Age: children are significantly more sensitive to anticholinergic effects  
- Concurrent anticholinergic medications: additive effects dramatically lower the threshold for toxicity  
- Individual CYP3A4 activity: affects scopolamine clearance

**Gruit (henbane beer):** Traditional preparation in northern European brewing added to beer for flavor and psychoactive effect; composition of such preparations is not quantified in published literature; replaced by hops post-1516. *Flag: traditional-use account only; no clinical data.*

---

## Safety & Toxicity

### Toxicity Profile

*H. niger* is a highly toxic plant; all parts (leaves, seeds, roots) contain pharmacologically active tropane alkaloids (Alizadeh 2014 [Ref 3]; Shim et al. 2022 [Ref 1]).

**LD50:** No published LD50 data for whole *H. niger* plant in humans found in the literature. For purified scopolamine and atropine, therapeutic and toxic doses in adults are in the milligram range; the margin between effect and severe toxicity is narrow. The EFSA established a group Acute Reference Dose (ARfD) of **0.016 µg/kg body weight** (sum of hyoscyamine + scopolamine, assuming equal potency) based on decreased heart rate in a human volunteer study (EFSA 2013 [Ref 11]).

**Mechanism of toxicity:** Full anticholinergic syndrome (peripheral + central) at doses achievable from plant material. The central effects (delirium, hallucinations, hyperthermia) are the most dangerous.

**Mnemonics for anticholinergic syndrome:** "Red as a beet (flushed skin), dry as a bone (anhidrosis, dry mucosae), blind as a bat (mydriasis), mad as a hatter (delirium), hot as a hare (hyperthermia), full as a flask (urinary retention), fast as a fiddle (tachycardia)."

### Case Reports and Population Data

- **Swiss Toxicology Information Center (1966–1994):** 3 severe *H. niger* poisoning cases causing anticholinergic syndrome, among 152 total severe plant poisoning cases over 29 years (Jaspersen-Schib et al. 1996 [Ref 12]). For comparison: *A. belladonna* = 42 cases, *D. stramonium* = 17 cases.  
- **European intoxication review (1966–2018):** *H. niger* poisonings primarily resulted from the plant being mistaken for other edible species; intentional use for psychoactive effect was much less common than for *Datura* (Fatur & Kreft 2020 [Ref 2]).  
- **Tropane alkaloid food poisoning incidents:** *H. niger* implicated in food contamination events when seeds contaminate cereals; contamination also found in herbal teas, blue/black berries, edible flowers, beans, buckwheat, soybean, linseed (Adamse et al. 2014 [Ref 13]).  
- **Australia, 1976:** Deliberate henbane flower chewing resulting in anticholinergic poisoning; authors noted "more widespread use of this plant among the drug-taking community" suggesting unreported cases (Sands & Sands 1976 [Ref 22]).

### Psychological Risks

- The primary psychoactive effect at toxic doses is **delirium** — an agitated, non-lucid state with hallucinations and confusion that is not voluntarily controllable  
- This is distinct from the controlled hallucinatory experiences associated with serotonergic psychedelics  
- **Reality testing is severely impaired** during anticholinergic delirium; users may act on delusions with risk of self-harm  
- Dose-response: all published psychoactive effects of *H. niger* are at doses overlapping with the toxic dose range; there is no established sub-toxic psychoactive threshold

### Herb–Drug Interactions

| Interaction | Mechanism | Evidence Basis |
|---|---|---|
| Grapefruit juice | CYP3A4 inhibition → increased scopolamine AUC (~142%) | Pharmacokinetic study (Renner 2005 [Ref 8]) |
| Tricyclic antidepressants | Additive anticholinergic burden | Pharmacodynamic; well-established mechanistic basis |
| Antihistamines (first-generation) | Additive anticholinergic burden | Pharmacodynamic; well-established mechanistic basis |
| Antipsychotics | Additive anticholinergic burden | Pharmacodynamic; well-established mechanistic basis |
| Benzodiazepines / alcohol | Additive CNS depression | Pharmacodynamic; well-established mechanistic basis |
| Cholinesterase inhibitors | Pharmacodynamic antagonism | Mechanistic (physostigmine as antidote) |

*Note: No clinical case reports of specific H. niger + pharmaceutical drug interactions found in published literature. The above are mechanistic predictions based on known pharmacology. The grapefruit juice interaction is the only one supported by a pharmacokinetic study.*

### Tolerance, Dependence, and Withdrawal

**Published data specific to *H. niger* or its alkaloids in a recreational/abuse context is absent from the literature.** 

- No tolerance studies for chronic scopolamine or hyoscyamine consumption in humans in recreational context  
- No dependence liability studies for *H. niger*  
- No withdrawal syndrome documented  
- In pharmaceutical use, scopolamine is classified as a non-addictive agent; it is not scheduled as a controlled substance in most jurisdictions based on abuse potential  
- The unpleasant, often terrifying nature of anticholinergic delirium strongly limits voluntary repeat use (Fatur & Kreft 2021 [Ref 29])

*Flag: This entire section is a gap — dependence and tolerance data for H. niger do not exist in the published literature to my knowledge.*

### Contaminant and Adulterant Risk

- Commercial food contamination is the primary adulterant risk: *H. niger* seeds can contaminate cereals (buckwheat, millet) and herbal teas during harvest and processing (Adamse et al. 2014 [Ref 13]; EFSA 2013 [Ref 11])  
- EFSA found that toddler dietary exposure could exceed the group ARfD on 11–18% of consumption days based on limited data from two EU member states (EFSA 2013 [Ref 11])  
- No regulatory limits for tropane alkaloids in food had been set at time of EFSA opinion (2013); EU has since moved toward maximum limits but this was beyond the scope of literature reviewed here  
- For deliberately obtained plant material: no published data on contamination or adulteration; plant morphology is distinctive enough that physical product adulteration is unusual  
- Intra-batch variability in alkaloid content is the primary safety-relevant variable for intentional use

### Vulnerable Populations

- **Children:** Substantially more sensitive to anticholinergic effects; 4 flowers can cause clinical poisoning in pre-school children (Alizadeh 2014 [Ref 3])  
- **Elderly:** Heightened anticholinergic sensitivity; significantly elevated risk of delirium; long-term anticholinergic exposure associated with dementia risk (Marzoughi et al. 2021 [Ref 32])  
- **Pregnant women:** Scopolamine crosses the placenta; should not be used without clinical supervision (Renner 2005 [Ref 8]); not classified as teratogenic but limited data  
- **Patients on anticholinergic medications (TCAs, antihistamines, antipsychotics):** Additive anticholinergic burden substantially lowers toxicity threshold  
- **Hepatic impairment:** May reduce alkaloid metabolism via CYP3A4; no specific *H. niger* data available  
- **Psychiatric conditions:** Delirium induction may worsen or precipitate psychotic episodes; no controlled data specific to *H. niger*

---

## Harm Reduction

### Published Risk Reduction Strategies

1. **Identification:** *H. niger* poisoning most commonly results from plant misidentification. Correct identification skills and consultation of authoritative botanical guides are the primary prevention tool (Fatur & Kreft 2020 [Ref 2])  
2. **No safe dose for intentional consumption:** The alkaloid content varies >10-fold between geographic strains; no threshold dose can be reliably established for plant material (Alizadeh 2014 [Ref 3])  
3. **Avoid concurrent anticholinergic substances:** Any concurrent use of tricyclic antidepressants, antihistamines, antipsychotics, or other anticholinergic medications drastically increases toxicity risk  
4. **Avoid alcohol and CNS depressants:** Additive sedation risk  
5. **Environmental setting:** Anticholinergic delirium produces disorientation and impaired reality testing; the user cannot maintain awareness of environment; safe setting is not achievable if delirium occurs

### Testing and Identification

- **Standard immunoassay drug panels do not detect scopolamine or hyoscyamine** — these are not included in routine urine drug screens (Konishi 2008 [Ref 24]; web search data)  
- **LC-MS/MS** can detect alkaloids in serum (limit 0.02 ng/mL) and urine (170–670 ng/mL in clinical poisoning cases) (Konishi 2008 [Ref 24])  
- **Urine detection window:** Demonstrated in a DFSA case at 41 µg/L, 18 h post-exposure (Melchior et al. 2023 [Ref 23])  
- **Hair detection:** 0.37 pg/mg at 5 weeks post-exposure (Melchior et al. 2023 [Ref 23])  
- Specific *H. niger* alkaloid testing requires laboratory request for tropane alkaloid screen, not standard panels

### Emergency Response

Acute *H. niger* poisoning requires emergency medical attention. Clinical management:  
1. **Supportive care** is the mainstay  
2. **Activated charcoal** (not ipecac) if ingestion was recent and airway is protected (Alizadeh 2014 [Ref 3])  
3. **Benzodiazepines** for agitation and seizure prevention  
4. **Physostigmine** (cholinesterase inhibitor) for severe anticholinergic delirium — shown superior to lorazepam in a randomized trial (Wang et al. 2021 [Ref 17]; Boley et al. 2019 [Ref 18])  
5. **Temperature management** for hyperthermia  
6. **Cardiac monitoring** for arrhythmia  
7. Approximately 85% of alkaloids are excreted within 24 hours (Alizadeh 2014 [Ref 3])

Poison Control Center (US): 1-800-222-1222

---

## Legal Status

### United States

**Federal:**  
- *H. niger* is **not scheduled** under the Controlled Substances Act (Title 21 of the US Code)  
- The plant is listed as a "poison" under 21 USC Title 21, Chapter 7, requiring products made from it to carry appropriate labeling ("for external use only" or "poison") with sales records maintained (Erowid [Ref 16])  
- The plant itself may be legally cultivated, purchased, possessed, and distributed without a license or prescription federally

**State-level:**  
- **Louisiana Act No. 159 (effective August 8, 2005):** Prohibits *H. niger* when intended for human consumption; permits possession, cultivation, growing, or harvesting for "aesthetic, landscaping, or decorative purposes" (Erowid [Ref 16])  
- **Tennessee:** A proposed ban was not enacted (Erowid [Ref 16])  
- **Multiple states — noxious weed designation (agricultural regulation, not controlled substance):** Washington, California, Colorado, Idaho, New Mexico, Nevada, South Dakota, Wyoming — and county-level lists in Montana [Ref 28]

### Canada

- **Federal:** Not scheduled as a controlled substance  
- **Alberta:** Designated noxious weed under provincial invasive species regulation — an agricultural/environmental designation, not a controlled substance classification [Ref 28]

### United Kingdom

- *H. niger* plant is not specifically scheduled under the Misuse of Drugs Act 1971  
- Pharmaceutical preparations of scopolamine and hyoscyamine are prescription-only medicines (POM) under UK medicines law  
- *Flag: Low confidence — could not find definitive UK-specific scheduling confirmation for the plant itself*

### Germany

- Multiple sources suggest Germany specifically regulates cultivation and possession of henbane beyond other European countries  
- *Flag: Low confidence — Germany-specific regulatory status for H. niger plant could not be definitively confirmed from available sources; human review required*

### Australia

- *H. niger* is not believed to be specifically scheduled as a controlled substance under federal Therapeutic Goods Administration (TGA) scheduling  
- Pharmaceutical scopolamine and hyoscyamine products are scheduled medicines (prescription)  
- Documentation of recreational use in the drug-taking community exists (Sands & Sands 1976 [Ref 22])  
- *Flag: Low confidence — Australian scheduling status for the plant itself could not be confirmed; human review required*

### International Treaties

- *H. niger* plant is **not listed** under the 1961 UN Single Convention on Narcotic Drugs, the 1971 Convention on Psychotropic Substances, or the 1988 Convention Against Illicit Traffic  
- The alkaloids scopolamine and hyoscyamine are not internationally controlled under these conventions in their plant-derived form; they are pharmaceutical agents listed on WHO Essential Medicines List  
- International treaty status does not restrict the plant, though individual nations may impose domestic regulations

---

## Clinical Trials

No clinical trials registered on ClinicalTrials.gov were found for *Hyoscyamus niger* as a whole plant or preparation (search returned zero results). Numerous trials exist for purified scopolamine (isolated pharmaceutical compound) for motion sickness, postoperative nausea, and other indications, but these test the isolated alkaloid, not *H. niger* plant preparations.

---

## Community Feedback Analysis

No community feedback was submitted in Part A2 of the brief.

---

## Gaps & Flags

### Critical Safety Data Gaps

1. **⚠️ DOSE FLAG — No verified dose ranges exist for any H. niger preparation.** The "4 flowers in a pre-school child" figure from Alizadeh (2014) is cited without a primary source in that review; the specific citation was not independently verified. All dose data comes from accidental poisoning cases, not controlled studies. No dose ranges should be presented in the article as anything other than illustrative of toxicity thresholds.

2. **LD50 absent:** No published LD50 for *H. niger* in humans. EFSA ARfD of 0.016 µg/kg bw for hyoscyamine + scopolamine is the only human-applicable regulatory value found.

3. **Alkaloid content in seeds specifically:** Published data conflict slightly — percentage-wise seeds have the lowest total alkaloid content by weight (0.05% European strains), but some sources describe seeds as having the "highest concentration." The discrepancy likely reflects differences between percentage of dry weight vs. total alkaloid per consumed quantity (seeds are small and often consumed in larger numbers). Clarification against a primary pharmacognosy quantification study would strengthen this.

4. **Egyptian vs. European strain alkaloid difference:** The >10-fold difference in total alkaloid content (0.7–1.5% vs. 0.05–0.17%) is highly safety-relevant. The Alizadeh 2014 review cites this but the original primary source should be verified.

### Ethnobotany Gaps (Flag for Human Review)

5. **Traditional-use sections rely on secondary sources:** The historical use data (ancient Greece, Vikings, medieval brewing) is documented in USDA ethnobotany web page and popular historical sources. The primary ethnobotanical monographs (Schultes & Hofmann, Rätsch) are not independently verified in this research pass — flag for human editorial review that these sections are based on traditional-use accounts.

6. **Avicenna/Ibn Sina claim:** Described in multiple sources but primary Arabic text not verified. Flag for human review.

### Herb–Drug Interactions

7. **⚠️ INTERACTION FLAG:** All herb–drug interactions except the grapefruit juice/CYP3A4 interaction (supported by pharmacokinetic study, Renner 2005 [Ref 8]) are based on pharmacodynamic mechanistic reasoning only. **No clinical case reports of specific H. niger + pharmaceutical drug interaction have been identified in published literature.** The severity of additive anticholinergic interactions is well-reasoned but not backed by specific H. niger case reports.

### Legal Status Gaps

8. **Germany legal status: LOW CONFIDENCE** — multiple sources suggest regulation but specific law or scheduling mechanism not confirmed.

9. **Australia legal status: LOW CONFIDENCE** — homeopathic preparations are sold commercially; a recreational use case was documented in MJA 1976; no definitive scheduling status found.

10. **UK legal status: LOW CONFIDENCE** — plant believed unscheduled but not confirmed against current Misuse of Drugs Act schedules.

### Pharmacology Gaps

11. **No pharmacokinetic data for H. niger plant preparations:** All PK data is for purified scopolamine formulations. The bioavailability of alkaloids consumed from plant material (oral tea, seeds, smoked) is unknown.

12. **Scopolamine vs. hyoscyamine ratio variability in intact plant:** This ratio varies with plant age, growing conditions, and geographic origin. No comprehensive study across multiple wild *H. niger* populations was found.

13. **Tolerance and dependence data absent:** No published data on tolerance development, dependence liability, or withdrawal for H. niger or its alkaloids in recreational/non-pharmaceutical contexts. Gap should be explicitly stated in the article.

14. **Smoking/inhalation preparation:** Used historically but no alkaloid yield data from this route for H. niger specifically.

15. **Duration data:** Based on pharmacokinetics of purified alkaloids and poisoning case resolution times; no controlled data on effect duration from plant preparations.

### Drug Test Detectability

16. **Standard panels do not detect H. niger alkaloids** — this is an important harm reduction point (users may erroneously believe they will test positive or negative on standard drug tests). No cross-reactivity with standard opiate, amphetamine, benzodiazepine, or cannabinoid assays.